Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00256776 · OUTCOME

Progression Free Survival

MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation · Source last updated 2021-10-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
3 year

Groups in this outcome

Thal + Dex + Velcade

Velcade (Bortezomib) Thalidomide Dexamethasone Median time to progression (primary end point): 19.5 months

Thal + Dex

Standard treatment Thalidomide Dexamethasone Median time to progression (primary end point): 13.8 months

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Thal + Dex + Velcade135
Thal + Dex134

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Thal + Dex + Velcade18.3Not reported15.520.6Not reported
Thal + Dex13.6Not reported9.916.1Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        15.5
        upper Limit
        20.6
        value
        18.3
      2. group Id
        OG001
        lower Limit
        9.9
        upper Limit
        16.1
        value
        13.6
denoms
  1. counts
    1. group Id
      OG000
      value
      135
    2. group Id
      OG001
      value
      134
    units
    Participants
dispersion Type
95% Confidence Interval
groups
  1. description
    Velcade (Bortezomib) Thalidomide Dexamethasone Median time to progression (primary end point): 19.5 months
    id
    OG000
    title
    Thal + Dex + Velcade
  2. description
    Standard treatment Thalidomide Dexamethasone Median time to progression (primary end point): 13.8 months
    id
    OG001
    title
    Thal + Dex
param Type
MEDIAN
reporting Status
POSTED
time Frame
3 year
title
Progression Free Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice